Topic resource collection
Approved comparison material connected to this topic.
479 resourcesRead both sides
A key research distinction of Selank from classical GABAergic anxiolytics (benzodiazepines) is the combination of: GABA-A positive modulation (anxiety reduction) + BDNF neuroplasticity enhancement (antidepressant and neuroprotect…
Kisspeptin-10 KNDy/GnRH/vasomotor (hot flush) KISS1R-Gαq-IP₃-Ca²⁺; LH pulsatility OVX Wistar; senktide challenge; icv delivery Epitalon Pineal melatonin; circadian; glymphatic clearance Telomerase-melatonin-BMAL1 axis Aged female…
Selank and Semax are frequently discussed together in nootropic and mental health research contexts because their mechanisms are complementary rather than redundant. Selank’s primary action involves enkephalin system modulation a…
Before selecting peptides for joint research, understanding their distinct mechanisms and research contexts is essential. BPC-157 VEGF pathway modulation, angiogenesis in peri-articular tissue Tendon-bone healing, ligament repair…
BPC-157 NOS stabilization, VEGF upregulation, cytokine modulation Acute injury resolution (0–14 days post-injury) 250–500 mcg SC twice daily 30+ preclinical studies; no human RCTs Best choice for acute traumatic injury and ligame…
Before choosing a peptide protocol, understand that the evidence base varies dramatically. What follows is a structured comparison of the compounds with published data. CJC-1295 + Ipamorelin GHRH agonist + ghrelin mimetic. Synerg…
MK 677 (Ibutamoren) Ghrelin receptor agonist. Stimulates continuous GH release 12.5–25mg daily Once daily (oral or subcutaneous) 15–25% increase in free testosterone over 8–12 weeks in clinical trials Best for sustained GH elevat…
Thymosin Alpha-1 TLR9 receptor activation in dendritic cells IL-12 upregulation → Th1 differentiation Phase III (adjuvant oncology) 42% increase in objective response rate when combined with checkpoint inhibitors Most evidence-ba…
Thymalin HPA axis modulation, cortisol reduction Hypothalamic glucocorticoid feedback Int J Immunopharmacol (cortisol reduction 22–28% over 8 weeks); pilot study showed anagen ratio improvement 58%→74% at 16 weeks 10mg subcutaneo…
Thymalin T-cell receptor modulation, reduces IL-6/TNF-alpha hepatic inflammation 5–10mg, 2–3x weekly, 4–8 week cycles Rodent NAFLD models show 41% reduction in inflammatory infiltrates (Molecular Medicine Reports, 2023) Best-supp…
BPC-157 VEGF/FGF-2 upregulation; FAK-paxillin pathway activation 30–50% faster callus formation; improved bone mineral density; enhanced angiogenesis 10 g/kg to 10 mg/kg (animal); human data absent Often marketed as 'heals everyt…
CJC-1295 (no DAC) + Ipamorelin GHRH analog + ghrelin agonist (pulsatile GH release) 70–85% above baseline 2–3× daily No desensitisation Multiple trials show 4–6% lean mass gain over 12–16 weeks Gold standard for bulking. Mimics n…
Tirzepatide (15mg weekly) Dual GLP-1/GIP receptor agonist. Delays gastric emptying, extends satiety, potentiates insulin secretion 20.9% at 72 weeks (SURMOUNT-1) GI side effects in 40–50% during titration; pancreatitis risk <1% F…
Thymosin Beta-4 Blocks RORγt transcription factor, reducing Th17 differentiation IL-23/IL-17 axis upstream 5–10mg SC twice weekly ~2 hours Animal models + Phase 1 human trials (wound healing) BPC-157 Modulates FGF receptors, norm…
Tendon/ligament repair (Achilles, plantar fascia, IT band) Upregulates VEGF and growth factors; promotes angiogenesis and tendon-to-bone healing 200–500 mcg/day subcutaneous 2–4 weeks for noticeable improvement in animal studies …
Before selecting a peptide protocol, understand that subcutaneous fat loss depends on sustained caloric deficit. Peptides enhance the process but don't replace it. The table below ranks compounds by clinical evidence for total bo…
The evidence base for peptide-assisted bone healing is uneven across compounds. Some peptides have been studied in controlled human trials; most remain confined to animal models. The table below compares mechanism, research depth…
CJC-1295 + Ipamorelin GH secretagogue (GHRH analog + ghrelin mimetic) Phase 2 trials showing 4.2% FFM increase, 7.8% VAT reduction over 12 weeks 100–300mcg ipamorelin + 100–200mcg CJC-1295, 2–3× weekly Mild: injection-site reacti…
Survodutide Dual GLP-1/glucagon agonist 12.5–14.7% Nausea (40%), diarrhea (28%), elevated heart rate (15%) Fastest fat oxidation due to hepatic glucagon signaling. Best for patients who plateau on GLP-1 monotherapy Mazdutide GLP-…
Before selecting a peptide for oxidative stress research, understand that each compound operates through distinct mechanisms. There is no universal 'best' peptide, only the most appropriate peptide for the specific oxidative stre…